09 Nov 2012, BioSpectrum Bureau , BioSpectrum
Singapore: Novartis planning to leverage on its R&D pipeline to taste commercial success through 2017. Continuing R&D productivity in the pharmaceuticals division has fueled Novartis' pipeline with 139 projects in clinical development, with more than 73 new molecular entities (NMEs) across a multitude of disease areas. Highlights include RLX030 and LCZ696 in heart failure as well as AIN457 in psoriasis and multiple sclerosis.
The Novartis group continues to lead the industry with 56 new approvals in the US, Europe, Japan and China since 2007. In 2012 alone, the pharmaceuticals division received nine approvals or positive recommendations.
Novartis, in the next 12 months, expects data read-out on 13 pivotal studies, nine filings and seven regulatory decisions. For the following 13-to-24 months, strong pipeline newsflow is expected to continue with a further 11 pivotal trials read-out, 11 filings and 10 regulatory decisions.
As evidenced by the recent launches of Afinitor, Seebri Breezhaler, Jakavi and Signifor, Novartis has a proven track record of bringing innovative products to market. With the current marketed portfolio, Novartis is expected to grow from the second half of next year, despite loss of exclusivity on mature brands like Diovan, Zometa and Aclasta. Oncology aims for continued growth through Glivec patent expiry.
The Novartis Oncology portfolio has delivered approvals for six indications including two new molecular entities, so far this year, and anticipates continued growth over the next five years. One of the major growth drivers, Afinitor, has five indications already approved and has the potential to exceed sales of $2 billion in breast cancer alone by 2017. In addition, launches of Jakavi and the planned launches of pipeline projects such as BKM120 for various tumors and LDK378 in lung cancer have the potential to contribute more than $1 billion in sales by 2017.